MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.710
-0.090
-2.37%
Closed 16:00 08/12 EDT
OPEN
3.790
PREV CLOSE
3.800
HIGH
3.870
LOW
3.710
VOLUME
61.14K
TURNOVER
--
52 WEEK HIGH
6.05
52 WEEK LOW
2.317
MARKET CAP
87.28M
P/E (TTM)
-6.3801
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ORMP stock price target is 9.67 with a high estimate of 17.00 and a low estimate of 6.00.

EPS

ORMP News

More
Company News for Jul 16, 2020
Zacks · 07/16 15:19
Oramed Reports Positive End Of Phase 2 Meeting With FDA For Oral Insulin
Benzinga · 07/15 12:56
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phas
PR Newswire · 07/15 12:55
Insulin in Pill Form Would Be a Bonanza for Oramed
Drug trials suggest first commercial oral insulin capsule may be on the horizon Continue reading...
GuruFocus.com · 07/08 22:09
HC Wainwright & Co. Maintains Buy on Oramed Pharmaceuticals, Lowers Price Target to $16
HC Wainwright & Co. maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Buy and lowers the price target from $20 to $16.
Benzinga · 06/22 11:51
ORMP: Positive Takeaways of Preliminary NASH Study Findings
Zacks Small Cap Research · 06/19 10:34
Oramed Pharmaceuticals shares are trading higher after the company announced the initial clinical trial results for the treatment of NASH with oral insulin.
Benzinga · 06/15 13:37
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
PR Newswire · 06/15 13:25

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About ORMP

Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.
More

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.